Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15333772 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL12847513 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL11223742 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL404573 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL15494655 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL24771437 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL7147808 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL20516514 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL22927890 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL3631711 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183661-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20160017323-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20150315594-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2015168635-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168532-A2 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168618-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-9145558-B2 | Compositions and methods for modulating HBV expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2015042447-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015006740-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140371432-A1 | NOVEL OLIGONUCLEOTIDE CONJUGATES AND USE THEREOF | BIONEER CORPORATION (KR) | 2014-12-18 | — | — | US | disclosed |
| WO-2014179626-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179629-A2 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179625-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179620-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371432-A1 | NOVEL OLIGONUCLEOTIDE CONJUGATES AND USE THEREOF | PHAX, NONO, RNASE1 | LMNA 1972/4885KMT2A 1373/4885POLB 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.